




GORE® SYNECOR
Intraperitoneal Biomaterial

MATERIAL INNOVATION
FOR PERMANENT
STRENGTH



Together, improving life



Innovative materials for specialised solutions

Gore makes a relentless commitment to improving lives through deliberate product innovation

- We have a comprehensive portfolio of biomaterials intended to meet the needs of hernia repair.
- Each biomaterial is specifically designed with the patient and surgeon in mind.
- Our biomaterials have a history of bringing sustainable clinical results to patients.


Consistent quality supports the confidence of providers, surgeons and patients

GORE® SYNECOR Intraperitoneal Biomaterial helps deliver the quality outcomes patients need

- Improves the economics of patient care.
- Potentially lower total cost of repair versus lightweight and midweight meshes, which have clinical literature case studies demonstrating failure due to inadequate strength in similar indications.¹⁻³

Facilitates the natural healing process with tri-layer biomaterial technology

The effect of pore size^{4,5}



As pioneers of the first mid-term bioabsorbable mesh with a targeted absorption period of six to seven months, (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ.), we are persistent in the pursuit of perfecting material solutions, so surgeons have more options when assessing the risk for complications and supporting complex cases.

Built upon tri-layer technology, GORE® SYNECOR Intraperitoneal Biomaterial is designed to give surgeons a strong repair with minimal permanent material.

Bringing the latest innovations to hernia repair

GORE® SYNECOR Intraperitoneal Biomaterial is a tri-layer hybrid solution designed for durable repair in complex patients Ventral hernia working group (VHWG 2) to facilitate healing⁶

Gore 3D PGA:TMC Web Scaffold


Provides rapid vascularisation and tissue ingrowth designed to facilitate healing (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ.).

PTFE

Latest generation PTFE fibre is designed for permanent strength. Strong and compliant: The PTFE knit is designed with a fibre diameter similar to lightweight mesh but with the strength of heavyweight mesh.

Non-porous PGA:TMC film

Provides intra-abdominal protection, minimising risk of adhesion formation⁷ (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ.).





Designed for ease of use during minimally invasive (laparoscopic, robotic) and open surgical procedures


- Material is flexible and conformable
- Material memory for easy unrolling, handling and optimal placement
- Absorbs fluids (i.e., blood)
- No pre-soaking needed, but may be dipped in sterile saline to facilitate handling



GORE® SYNECOR Intraperitoneal Biomaterial is available in sizes ranging from 12 cm circle to 20 cm x 30 cm rectangle.


Rapid vascularisation and tissue ingrowth⁸

Vascularity within Gore 3D PGA:TMC web increases over time⁷



* Data on file 2008; W. L. Gore & Associates, Inc; Flagstaff, AZ.



Material replaced by patient's own tissue⁹



† Cells and blood vessels make up remaining volume. GORE® BIO-A® Hernia Plug.

Parietal layer: Gore 3D PGA:TMC Web Scaffold provides rapid vascularisation and tissue ingrowth designed to facilitate healing (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ.)

- Enhances tissue response: Designed to promote rapid cell migration and vascularisation (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ.).
- Designed to break down primarily by hydrolysis and provide tissue uniformity and consistency.
- Within seven days: Tissue shows vascularity.⁸
- At 30 days: Tissue ingrowth (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ.).
- Tissue ingrowth is present throughout the Gore 3D PGA:TMC Web Scaffold with various densities around the knit fibres and within the scaffold.
- Ingrowth is vascularised, organised and filled the macropores.
- At 180 days: Tissue generation (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ.).
- Gore 3D PGA:TMC Web Scaffold is absorbed, leaving organised fibrous tissue ingrowth.
- Minimal tissue encapsulation of the PTFE knit.



Arrows indicate area where blood vessels are penetrating through the PTFE knit at seven days post-implantation.⁸

Latest generation PTFE fibre is designed for permanent strength


Mid-layer: Macroporous knit of dense, monofilament PTFE fibres

The treatment of ventral hernias with prosthetic devices has reduced recurrence rates but has led to questions concerning infection. Open hernia repair has been associated with infection rates from 3 percent to 18 percent.¹⁰ Laparoscopic ventral hernia repair has been associated with lower incidence of infection.¹⁰


The macroporous knit of dense, monofilament PTFE fibres may reduce the risk of bacterial adherence¹¹ and along with increased vascularity⁵ may aid in the overall treatability of the device to minimise the need for removal if postoperative infection were to occur (data on file 2020; W. L. Gore & Associates, Inc; Flagstaff, AZ.).

Optimal porosity


The PTFE knit of GORE® SYNECOR Intraperitoneal Biomaterial has a large pore size (1–3 mm). As demonstrated in animal models, large pore sizes have been shown to improve mechanical strength of tissue ingrowth¹² and reduce scar plate formation.¹³



GORE® SYNECOR Biomaterial:
Macroporous knit of dense monofilament PTFE fibre



Polypropylene knit



Unique tri-layer hybrid device:
GORE® SYNECOR Intraperitoneal Biomaterial

Provides strength for large defects and higher BMIs


Strong and compliant

PTFE knit is designed with a fibre diameter similar to lightweight mesh but with the strength of heavyweight mesh.

Permanent strength

Burst strength is > 500 N. This provides strength for large defects and higher BMIs at almost two times the strength requirement for bridging ventral hernia repairs (data on file 2016; W. L. Gore & Associates, Inc; Flagstaff, AZ.).^{14,15}

The macroporous knit of dense, monofilament PTFE fibre provides permanent strength designed for a durable repair.



Durable strength of the material helps to support robust healing

- May lower risk of recurrence versus lightweight and midweight meshes, which may have inadequate strength in complex patients (VHWG 2).¹⁻³

BD is a trademark of Becton, Dickinson and Company.

ETHICON and ULTRAPRO are trademarks of Ethicon, Inc., a Johnson and Johnson Company.

MEDTRONIC, PARIETEX and SYMBOTEX are trademarks of Medtronic, Inc.

PTFE fibres may reduce the risk of bacterial adherence¹¹

Bacterial adherence was examined among various materials including, the PTFE knit of GORE® SYNECOR Intraperitoneal Biomaterial, various polypropylene knits and a polyvinylidene fluoride/polypropylene construct.


The materials were incubated in staphylococcus aureus overnight, rinsed and subjected to staining and analysis through confocal microscopy.

This allowed for analysis of where bacteria attached.

Overall, bacteria localise to the knots and fibre surfaces of all test articles examined in this study.


Confocal images suggest that no bacteria are located within the PTFE knit fibres and overall fewer bacteria are located on PTFE knit fibres than other materials.

PTFE knit had the least bacterial adherence on the surface when compared with other competitive polypropylene knits.¹¹




Gore's latest-generation PTFE macroporous knit.


PTFE knit (10×)




Polypropylene knit (10×)



Lightweight polypropylene knit (10×)



Polyvinylidene/Polypropylene knit (10×)



Staphylococcus aureus stains green; red represents the fibre materials as reflected light.

Designed to provide predictable performance

Minimal contraction

All biomaterials, including polypropylene, polyester and PTFE, will contract to some degree after implantation due to the activity of myofibroblasts during wound healing. Animal studies show GORE® SYNECOR Intraperitoneal Biomaterial has minimal contraction at 30 and 180 days (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ.).

Protection from abdominal adhesion formation may lower the risk of postoperative complications and reoperation.

Visceral Layer: Non-porous PGA:TMC film provides intra-abdominal protection, minimising risk of adhesion formation⁷ (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ.).

- PGA:TMC film: A non-porous film, minimises visceral attachment to the material.
- Designed to limit cellular penetration.
- Film provides a uniform surface while the neoperitoneum is forming.
- PGA:TMC film absorbs in six to seven months (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ.).
- Animal studies have shown no mid-substance adhesions to the material at both 30 and 180 days (data on file 2015; W. L. Gore & Associates, Inc; Flagstaff, AZ.).

No Gore biomaterials are human, animal or tissue-derived.

These biomaterials eliminate the risk of disease transmission by tissue-derived products, residual cellular debris or conflict with religious beliefs/cultural practices.¹⁶

Innovative materials for specialised solutions

Competitor reference chart

Based on patient selection criteria, clinicians may utilise GORE® SYNECOR Intra-peritoneal Biomaterial in place of the following products:

Company	Product name	Biosynthetic mesh	Permanent mesh	Composite mesh*
BD®	COMPOSIX E/X Mesh		●	
BD®	COMPOSIX L/P Mesh		●	
BD®	SEPRAMESH IP Composite			●
BD®	VENTRALIGHT ST Mesh			●
BD®	VENTRIO Hernia Patch		●	
BD®	VENTRIO ST Hernia Patch			●
BD®	PHASIX ST Mesh	●		
MEDTRONIC	PARIETEX Optimized Composite (PCOx) Mesh			●
MEDTRONIC	SYMBOTEX Composite Mesh			●

* Composite meshes are permanent mesh with an absorbable visceral protection layer.

Sizing

Catalogue number	Description
GKFC12E	12 cm diameter circle
GKJV1015E	10 cm × 15 cm oval
GKJV1520E	15 cm × 20 cm oval
GKFR2025E	20 cm × 25 cm rectangle
GKFR2030E	20 cm × 30 cm rectangle

BD, COMPOSIX, PHASIX, SEPRAMESH, VENTRALIGHT and VENTRIO are trademarks of Becton, Dickinson and Company.

MEDTRONIC, PARIETEX and SYMBOTEX are trademarks of Medtronic, Inc.

References

1. Petro CC, Nahabet EH, Criss CN, *et al.* Central failures of lightweight monofilament polyester mesh causing hernia recurrence: a cautionary note. *Hernia* 2015;19(1):155-159.
2. Cobb WS, Warren JA, Ewing JA, Burnikel A, Merchant M, Carbonell AM. Open retromuscular mesh repair of complex incisional hernia: predictors of wound events and recurrence. *Journal of the American College of Surgeons* 2015;220(4):606-613.
3. Warren JA, McGrath SP, Hale AL, Ewing JA, Carbonell AM 2nd, Cobb WS 4th. Patterns of recurrence and mechanisms of failure after open ventral hernia repair with mesh. *American Surgeon* 2017;83(11):1275-1282.
4. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM. Engineering the tissue which encapsulates subcutaneous implants. II. Plasma-tissue exchange properties. *Journal of Biomedical Materials Research* 1998;40(4):586-597.
5. Holt DJ, Grainger DW. Host response to biomaterials. In: Hollinger JO, ed. *An Introduction to Biomaterials*. 2nd ed. Boca Raton, FL: CRC Press; 2012;6:91-118.
6. Ventral Hernia Working Group, Breuing K, Butler CE, *et al.* Incisional ventral hernias: review of the literature and recommendations regarding the grading and technique of repair. *Surgery* 2010;148(3):544-558.
7. Matthews BD. Absorbable and nonabsorbable barriers on prosthetic biomaterials for adhesion prevention after intraperitoneal placement of mesh. *International Surgery* 2005;90(3)Supplement:530-534.
8. Crawford N. *Assessment of Vascularity via Micro CT in Various Patch Devices*. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2016. [Final study report]. 2344TL.
9. Morales-Conde S, Flores M, Fernández V, Morales-Méndez S. Bioabsorbable vs polypropylene plug for the "Mesh and Plug" inguinal hernia repair. Poster presented at the 9th Annual Meeting of the American Hernia Society. February 9-12, 2005; San Diego, CA.
10. LeBlanc KA, Heniford BT, Voeller GR. Innovations in ventral hernia repair. Materials and techniques to reduce MRSA and other infections. *Contemporary Surgery* 2006;62(4)Supplement:1-8.
11. Clinger L. *PTFE Knit Microbial Placement*. Flagstaff, AZ; W. L. Gore & Associates, Inc; 2018. [Work plan]. WP110158.
12. Lake SP, Ray S, Zihni AM, Thompson DM Jr, Gluckstein J, Deeken CR. Pore size and pore shape—but not mesh density—alter the mechanical strength of tissue ingrowth and host tissue response to synthetic mesh materials in a porcine model of ventral hernia repair. *Journal of the Mechanical Behavior of Biomedical Materials* 2015; 42:186-197.
13. Klinge U, Klosterhalfen B, Birkenhauer V, Junge K, Conze J, Schumpelick V. Impact of polymer pore size on the interface scar formation in a rat model. *Journal of Surgical Research* 2002;103(2):208-214.
14. Zhu LM, Schuster P, Klinge U. Mesh implants: an overview of crucial mesh parameters. *World Journal of Gastrointestinal Surgery* 2015;7(10):226-236.
15. Klinge U, Klosterhalfen B, Conze J, *et al.* Modified mesh for hernia repair that is adapted to the physiology of the abdominal wall. *European Journal of Surgery* 1998;164(12):951-960.
16. Jenkins ED, Yip M, Melman L, Frisella MM, Matthews BD. Informed consent: cultural and religious issues associated with the use of allogeneic and xenogeneic mesh products. *Journal of the American College of Surgeons* 2010;210(4):402-410.

 Consult Instructions
for Use
eifu.goremedical.com

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only

Products listed may not be available in all markets.

BD, COMPOSIX, PHASIX, SEPRAMESH, VENTRALIGHT and VENTRIO are trademarks of Becton, Dickinson and Company.
ETHICON and ULTRAPRO are trademarks of Ethicon, Inc.
MEDTRONIC, PARIETEX, and SYMBOTEX are trademarks of Medtronic, Inc.

GORE, *Together, improving life*, SYNECOR and designs are trademarks of W. L. Gore & Associates.
© 2022 W.L. Gore & Associates (Australia) Pty. Ltd. 22623150-EN JULY 2022

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 6733 2882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673
United States Flagstaff, AZ 86003 800 437 8181 928 779 2771

